Locations:
SearchDebating second-line treatment options
When it comes to effective second-line therapies for patients with steroid-resistant idiopathic thrombocytopenic purpura, clinicians debate whether splenectomy should remain an early intervention or whether drugs such as rituximab can delay or eliminate the need for splenectomy.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Keith McCrae, MD, a hematologist at Cleveland Clinic’s Taussig Cancer Institute, discusses the advantages and disadvantages of the two forms of treatment, including individualized patient needs, cost and risk factors.
Read the full point and counterpoint article in ASH Clinical News.
Advertisement
Advertisement
Finally, promising new therapies for this difficult disease
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials